← All Newamsterdam Pharma CO NV filings

Newamsterdam Pharma CO NV 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
NAMS
Newamsterdam Pharma CO NV
10-K: NewAmsterdam Pharma Reports Positive Phase 3 Results, Charts Path to Regulatory Approval
NewAmsterdam Pharma's 10-K filing highlights successful Phase 3 trials for obicetrapib and its fixed-dose combination, paving the way for potential regulatory submissions and commercialization.
NASDAQ
NAMS
Newamsterdam Pharma CO NV
10-K: NewAmsterdam Pharma Details Share Structure and Warrant Terms in SEC Filing
NewAmsterdam Pharma's recent SEC filing outlines the terms of its ordinary shares and warrants, including redemption options and anti-dilution adjustments.